Early Symptoms of Bladder Cancer

The most recognisable symptom of bladder cancer is blood in the urine (haematuria) which may cause the urine to appear pink, red or cola-coloured. Haematuria in bladder cancer is often painless, which makes it particularly important not to dismiss. Other symptoms include increased frequency of urination, burning or pain during urination, persistent urge to urinate even when the bladder is not full, pelvic pain in more advanced disease, and lower back pain, particularly on one side. Painless haematuria even if it appears only once or is detected on a dipstick urine test should always prompt specialist urological assessment.

What Causes Bladder Cancer?

Smoking is the single most important modifiable risk factor for bladder cancer, responsible for the majority of cases. Tobacco chemicals are processed by the body and excreted in urine, where they remain in contact with the bladder lining for prolonged periods. Additional risk factors include chemical exposure occupational exposure to aromatic amines found in dyes, rubber, leather and paint industries chronic urinary infections, particularly with Schistosoma haematobium, prior pelvic radiation, use of cyclophosphamide chemotherapy, and a personal or family history of bladder cancer.

Types of Bladder Cancer

Bladder cancers are classified by cell of origin, depth of invasion, and histological grade — all of which critically influence treatment strategy.

Urothelial Carcinoma (Transitional Cell Carcinoma): The most common type, accounting for approximately 90% of bladder cancers in developed countries and the majority in India. Arises from the urothelium the specialised epithelium lining the bladder, ureters and renal pelvis. Can be:

• Non-muscle-invasive (NMIBC): Confined to the inner lining (Ta, T1, CIS). Treated with TURBT and intravesical therapy.

• Muscle-invasive (MIBC): Has penetrated the bladder muscle (T2 and beyond). Requires radical cystectomy or bladder-preserving chemoradiation.

Squamous Cell Carcinoma: Accounts for approximately 3–8% of bladder cancers. Associated with chronic bladder irritation including Schistosoma haematobium infection (endemic in parts of Africa and the Middle East), chronic catheterisation and bladder stones. Typically presents at a more advanced stage.

Adenocarcinoma: Rare; may arise from the urachal remnant (urachal adenocarcinoma) or from metaplastic glandular cells in the bladder wall (non-urachal). Urachal adenocarcinoma arises at the bladder dome and requires wide excision including the urachal ligament.

Small Cell (Neuroendocrine) Carcinoma of the Bladder: Rare and highly aggressive. Treated with platinum-based chemotherapy similar to SCLC protocols.

Bladder Sarcoma: Very rare; includes leiomyosarcoma and rhabdomyosarcoma (more common in children). Requires specialised sarcoma protocols.

Carcinoma In Situ (CIS): A high-grade, flat, non-invasive lesion classified as NMIBC but carries a high risk of progression to muscle-invasive disease. Treated aggressively with BCG intravesical therapy.

Bladder cancer is also graded low grade (slow-growing, rarely progresses) and high grade (faster-growing, higher risk of invasion and metastasis). Both grade and stage guide the intensity of treatment and surveillance.

​Diagnosis

Cystoscopy — direct visualisation of the bladder using a thin flexible or rigid camera — is the definitive diagnostic procedure. CT urogram provides imaging of the entire urinary tract, which is important as urothelial cancer can also develop in the upper urinary tract (kidneys and ureters), where periodic surveillance imaging is also performed. Urine cytology and urine biomarker tests may also be used. Muscle invasion is assessed on biopsy, as this fundamentally changes the treatment approach.

Treatment — Including TURBT Surgery

TURBT (Transurethral Resection of Bladder Tumour): TURBT surgery in Noida is the standard initial treatment for non-muscle-invasive bladder cancer (NMIBC). It involves removing the tumour from the bladder lining using a resectoscope passed through the urethra no external incision is required.

Intravesical Therapy: BCG (Bacillus Calmette-Guérin) — originally developed as a tuberculosis vaccine is instilled directly into the bladder to stimulate the immune system against cancer cells, reducing recurrence and progression risk in high-risk non-muscle-invasive disease.

Is Bladder-Preserving Treatment Possible? For selected patients with muscle-invasive bladder cancer (MIBC) who are not suitable for or decline radical cystectomy, bladder-preserving trimodality therapy combining TURBT, chemotherapy and radiation is an established alternative supported by NCCN and ESMO guidelines.

Radical Cystectomy: For muscle-invasive bladder cancer, radical removal of the bladder with urinary diversion remains the standard curative surgical option. 

Immunotherapy: For advanced or metastatic bladder cancer, immunotherapy agents such as pembrolizumab are established second-line treatment options per NCCN and ESMO guidelines. The bladder cancer treatment cost in Noida depends on stage, treatment type, and surveillance requirements

How Often Does Bladder Cancer Recur?

Recurrence is a defining feature of non-muscle-invasive bladder cancer a significant proportion of patients experience recurrence within five years. This is why regular surveillance cystoscopies typically every three to six months initially are an essential and non-negotiable part of long-term bladder cancer management.